Huma Therapeutics secures $80m in Series D funding to expand digital health platforms
The financing round featured backing from investors including AstraZeneca, Hitachi Ventures, and Leaps by Bayer.
Healthcare technology company providing digital platforms for remote patient monitoring, companion applications, and clinical trials.
Healthcare technology company Huma Therapeutics has secured $80m in a Series D financing round to support its ongoing development. The investment saw participation from a range of new and existing backers, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer. HSBC Bank plc advised the company during the transaction.
The capital arrives alongside the launch of the Huma Cloud Platform, a generative artificial intelligence system designed to help health organisations build and deploy digital applications quickly. Huma intends to use the fresh backing to expand its technological capabilities and scale its operations across international markets.
The company works with hospitals, research institutions, and pharmaceutical firms globally to power remote monitoring and decentralised clinical trials. Its technology has been deployed across more than 3,000 healthcare facilities worldwide.
Investor perspective
"We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care."
Juergen Eckhardt
EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing, Leaps by Bayer
Use of funds
- 01Continue product development
- 02Expand into international markets
Investors
Categories
About the company
Huma Therapeutics
Huma Therapeutics builds digital health platforms for care and research.